Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom 
Oil Prices Steady as US-Iran Nuclear Talks and Rising Crude Inventories Shape Market Outlook 
Asian Markets Slide as Nvidia Earnings, U.S.-Iran Tensions and AI Valuations Weigh on Investor Sentiment 
Amazon’s $50B OpenAI Investment Tied to AGI Milestone and IPO Plans 
Gold Prices Steady in Asia, Set for Strong February Gains on Safe-Haven Demand 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
Qantas Shares Plunge 10% as Iran Strikes Send Oil Prices Soaring and Disrupt Global Flights 
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute 
Strait of Hormuz LNG Crisis Triggers Global Energy Market Shock 
Nintendo Share Sale: MUFG and Bank of Kyoto to Sell Stakes in Strategic Unwinding 
Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models 
Tokyo Core Inflation Slows Below 2%, Complicating BOJ Rate Hike Outlook 
Japan Manufacturing PMI Jumps to Four-Year High as Global Demand Strengthens 
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand 
Trump Media Weighs Truth Social Spin-Off Amid $6B Fusion Energy Pivot 
FAA Plans Flight Reductions at Chicago O’Hare as Airlines Ramp Up Summer Schedules 
Ecuador Raises Tariffs on Colombian Imports to 50% Amid Border Security Dispute 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
